🏛️ Verified NIH Record • Updated 2025-11-07
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant (NCT06109181)
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
🔵 Active, Not Recruiting Phase1 / Phase2 📋 Clinical Research Protocol Sponsor: Lexeo Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Who can join: Review the eligibility criteria below.
Location: Stanford University — Stanford, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
- LX2020 (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Stanford University — Stanford, California
- Johns Hopkins University — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- University of Rochester — Rochester, New York
- Medical University of South Carolina — Charleston, South Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Arrhythmogenic Cardiomyopathy
Explore by condition: All Arrhythmogenic Cardiomyopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.